GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diagnamed Holdings Corp (OTCPK:DGNMF) » Definitions » NonCurrent Deferred Liabilities

DGNMF (Diagnamed Holdings) NonCurrent Deferred Liabilities : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Diagnamed Holdings NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Diagnamed Holdings's non-current deferred liabilities for the quarter that ended in Dec. 2024 was $0.00 Mil.

Diagnamed Holdings NonCurrent Deferred Liabilities Historical Data

The historical data trend for Diagnamed Holdings's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diagnamed Holdings NonCurrent Deferred Liabilities Chart

Diagnamed Holdings Annual Data
Trend Sep21 Sep22 Sep23 Sep24
NonCurrent Deferred Liabilities
- - - -

Diagnamed Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Diagnamed Holdings NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Diagnamed Holdings's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Diagnamed Holdings Business Description

Traded in Other Exchanges
Address
82 Richmond Street East, Toronto, ON, CAN, M5C 1P1
Diagnamed Holdings Corp is engaged in developing a platform of software-based prescription digital therapeutic products (PDT Products) with the potential to improve early detection of neurological disorders, overall patient health and lower healthcare costs. Its products include, CERVAI which is a brain health AI platform leveraging that aims to predict and monitor brain age and provide actionable insights for mental health and neurodegenerative disorders. It is also investigating other technological applications such as BrainAge and BrainTremor.